Bottomed low float bio ready to bounce

AI Summary

Author argues IMRN is a bottomed low-float biotech with military backing and upcoming catalysts, poised to bounce.

IMRN — LONG The author argues IMRN is a bottomed low-float pharmaceutical play with huge backing from the military and Department of Defense, and ongoing research relationships with major US military institutions. He cites upcoming catalysts: the planned launch of ProIBS any day now (originally scheduled for Q4) and the initiation of a phase 2 clinical trial for IMM-200 in the first half of 2026. He also notes no dilution with cash for the next year and a large gap to fill on the daily chart from a 52-week high of $2.50 down to $1.00.

IMRN is a pharmacuetical play with huge backing by the military and department of defense.

Score 1

Comments 3

▶ Full Post Text

Ideas

u/blakeley314 Reddit r/pennystocks

Bottomed low-float biotech with military catalysts

The author argues IMRN is a bottomed low-float pharmaceutical play with huge backing from the military and Department of Defense, and ongoing research relationships with major US military institutions. He cites upcoming catalysts: the planned launch of ProIBS any day now (originally scheduled for Q4) and the initiation of a phase 2 clinical trial for IMM-200 in the first half of 2026. He also notes no dilution with cash for the next year and a large gap to fill on the daily chart from a 52-week high of $2.50 down to $1.00.

▶ Full Post Text

Ideas

More from Reddit — r/pennystocks